NCT05245474 - Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer | Biotech Hunter

Enrollment

186

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

March 1, 2024

Study Completion Date

September 1, 2029

Conditions

Locally Advanced Rectal Cancer

Interventions

COMBINATION_PRODUCT

Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)

Tislelizumab is added to long-course chemoradiation (CRT) of LARC patients, with CRT+concurrent Tislelizumab for Arm 1, CRT+sequential Tislelizumab for Arm 2, and CRT only for Arm 3

Trial Locations (8)

100050

RECRUITING

Beijing Friendship Hospital, Capital Medical University, Beijing

Unknown

COMPLETED

Beijing Cancer Hospital, Beijing

COMPLETED

Beijing Chaoyang Hospital, Capital Medical University, Beijing

COMPLETED

Beijing Hospital, Beijing

RECRUITING

Peking Union Medical College Hospital, Beijing

RECRUITING

Peking University First Hospital, Beijing

RECRUITING

Peking University People's Hospital, Beijing

COMPLETED

Xuanwu Hospital, Capital Medical University, Beijing